Commodore Capital
Overview
Commodore Capital is invested in the early stages of a major innovation cycle in biopharmaceuticals.
Investment Focus
- Focus on innovative biopharmaceutical companies
- Preference for early-stage venture investments
- Commitment to improving patient outcomes
Portfolio Companies
Reach Commodore Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Commodore Capital
What sectors does Commodore Capital invest in?
Commodore Capital invests in Healthcare, Biotechnology, Pharmaceutical, Life Science, Clinical Trials and Therapeutics, and is based in New York, United States. Commodore Capital is listed as a vc in the ConnectSafely investor database.
What stage does Commodore Capital invest at?
Commodore Capital backs companies at Seed, Series A, Series B, Growth, Late Stage and Pre-IPO, writing cheques of 10M - 200M.
Which regions does Commodore Capital invest in?
Commodore Capital invests across United States, United Kingdom and France.
What companies has Commodore Capital invested in?
Commodore Capital's portfolio includes Shoreline Biosciences, Kronos Bio, Nimbus Therapeutics, Enliven Therapeutics, Cogent Biosciences, C4 Therapeutics, Unum Therapeutics and Third Harmonic Bio.
How do I contact Commodore Capital?
Commodore Capital's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.
Last updated · Source: ConnectSafely investor database
